1050 TREATING RELAPSE WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN AND AMANTADIN FOR EITHER 72 OR 48 WEEKS (IN PATIENTS WITH HCV-TYPE 1/3 INFECTION): RESULTS FROM THE TRELA-STUDY